非ST段抬高型心肌梗死患者药物治疗和PCI治疗预后比较  

Prognosis comparison of drug treatment and PCI treatment on non-ST-segment-elevation myocardial infarction

作　　者：张莉[1] 翟昌林[2] 

机构地区：[1]台州市第一人民医院心血管内科,浙江台州318020 [2]嘉兴市第一医院心血管内科,浙江嘉兴314000

出　　处：《中华全科医学》2016年第11期1813-1815,1847,共4页Chinese Journal of General Practice

基　　金：2015年浙江省医药卫生科技计划项目(2015KYB-387)

摘　　要：目的探讨药物治疗和PCI治疗非sT段抬高型心肌梗死患者的预后情况。方法选择2009年1月-2014年12月台州市第一人民医院心血管内科非sT段抬高型心肌梗死药物治疗患者623例和药物治疗＋PCI治疗患者412例作为研究对象。观察药物治疗组和药物治疗＋PCI治疗组的终点事件发生率和中位生存时间，药物治疗组和药物治疗＋PCI治疗组不同TIMI评分和不同年龄的终点事件发生率。结果药物治疗组的主要终点事件和次要终点事件的发生率均高于药物治疗＋PCI治疗组（P〈0．05）。药物治疗组的主要终点事件及次要终点事件的中位生存时间均低于药物治疗＋PCI治疗组（P〈0．05）。药物治疗组和药物治疗＋PCI组TIMI评分0—2分者的主要终点事件和次要终点事件的发生率比较差异没有统计学意义（P〉0．05），药物治疗组TIMI评分3—5分和6—7分主要终点事件及次要终点事件的发生率均高于药物治疗＋PCI组（P〈0．05）。药物治疗组的〈65岁患者主要终点事件及次要终点事件的发生率和药物治疗＋PCI组比较差异没有统计学意义（P〉0．05），药物治疗组的65—75岁及〉75岁患者主要终点事件及次要终点事件的发生率均高于药物治疗＋PCI组（P〈0．05）。结论PCI治疗能够降低非sT段抬高型心肌梗死不良终点事件的发生率，延长中位生存时间，对TIMl分级中高危患者及年龄〉65岁的患者进行PCI介入治疗能够有效改善其预后。Objective To explore the prognosis of drug therapy and PCI treatment of non-ST segment elevation myocardial infarction. Methods Total 623 cases of non-ST-segment-elevation myocardial infarction receiving drug treatment （ drug treatment group） and 412 cases of drug therapy with PCI（ drug therapy ＋ PCI treatment group） in Taizhou First People＇ s Hospital were enrolled into this study. The incidence of endpoint events and median survival time in both groups were ob- served,and TIMI score and age differentiation of endpoint events were compared. Results The incidence of the primary endpoint events and secondary endpoint events of the drug treatment group were higher than that of the drug therapy ＋ PCI treatment group（P 〈 0.05）. The median survival time of the primary endpoint events and secondary endpoint events of drug treatment group were lower than that of drug therapy ＋ PCI treatment group（ P 〈 0.05 ）. The difference of the inci- dence of primary endpoint events and secondary endpoint events in the drug treatment group and drug therapy ＋ PCI treat- ment group with TIMI score 0 - 2 was not statistically significant（ P 〉 0.05 ） , the incidence of primary endpoint events and secondary endpoint events in the drug treatment group with TIMI score 3 -5 and 6 -7 were higher than that of the drug therapy ＋ PCI treatment group（ P 〈0.05 ）. The difference of incidence of the primary endpoint events and secondary end- point events in the drug treatment group and drug therapy ＋ PCI treatment group with 〈 65-year-old patient was not statis- tically significant（ P 〉 0.05） ,the incidence of primary endpoint events and secondary endpoint events in the drug treat- ment group with 65 -75 years and 〉 75 years were higher than that of the drug therapy ＋ PCI group（P 〈 0.05）. Conclu- sion PCI therapy can reduce the incidence of adverse outcome events of non-ST-segment-elevation myocardial infarc- tion, prolonged median survival time,improve the prognosis of patients with TI

关 键 词：非ST段抬高型心肌梗死 药物治疗 PCI介入治疗 预后 

分 类 号：R542.22[医药卫生—心血管疾病] R972[医药卫生—内科学]